GLP-1 Receptor Agonist Market Size
US$ 28.07
retatrutide sign up ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide leads in obesity treatment
Description
Development 131:93104
Diabetic neuropathy benefits Perhaps most relevant to the semaglutide discussion, research demonstrates that GLP-1 receptor agonists can ameliorate diabetic neuropathic pain by inhibiting neuroinflammation in the spinal cord
Patients experiencing weight regain after bariatric surgery should initially contact their GP or bariatric surgical team to discuss concerns
GIP+GLP-1, with its unique mechanism of action, has already achieved significant results in diabetes treatment and weight management
